Leadership Announcement

Drs. Pollock and Farrar named as new leaders of OSUCCC and The James

Raphael PollockWilliam FarrarRaphael Pollock, MD, PhD, has been named director of The Ohio State University Comprehensive Cancer Center (OSUCCC), and William Farrar, MD, has been named interim CEO of the James Cancer Hospital and Solove Research Institute.

Ohio State University President Michael V. Drake, MD, announced their appointments to fill vacancies created when former OSUCCC Director and James CEO Michael A. Caligiuri, MD, stepped down from both positions in November. Caligiuri, who had been OSUCCC director since 2003 and James CEO since 2008, joined City of Hope National Medical Center in Duarte, California, as president and physician-in-chief.

Pollock, who also has served as director of the Division of Surgical Oncology at Ohio State and is in the Translational Therapeutics Program at the OSUCCC – James, was recruited to the university in 2013 from MD Anderson Cancer Center in Houston, where he had worked for 31 years. Because of his new role as CCC director, he will no longer direct the Division of Surgical Oncology.

Farrar, a surgical oncologist who serves as director of the Stefanie Spielman Comprehensive Breast Center and director of medical credentialing at the OSUCCC – James, has been on The James medical staff since the hospital opened in 1990. He was mentored by the late Arthur G. James, MD, for whom the hospital is named. Farrar also is in the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James.

Cohn appointed to new leadership role 

David CohnDavid Cohn, MD, professor and director of the Division of Gynecologic Oncology at Ohio State, has been named director of medical affairs at the James Cancer Hospital and Solove Research Institute, replacing William Farrar, MD, in this capacity. Farrar is interim CEO of The James and director of the Stefanie Spielman Comprehensive Breast Center.

Cohn is only the third medical affairs director at The James in the nearly three decades since the hospital opened. He is a gynecologic oncologist and a member of the OSUCCC – James Translational Therapeutics Program. As director of medical affairs, he will be responsible for ensuring that The James medical staff remains focused on delivering the highest quality and safest clinical care to patients. In this role, he will report to The James CEO.

Sign up to receive publications from the OSUCCC – James

Sign Up Now

Contact The James

General Inquiries




460 W. 10th Avenue
Columbus, OH 43210

Contact Us

Meet the Leaders

Leadership & Executive Cabinet at The James

Learn More